ERBB2 and neoplasm: Our study explores the application of HER2-specific CAR NK cells against both trastuzumab-sensitive (CD44−) and trastuzumab-resistant (CD44+) HER2-positive tumor models, providing insight into the potential and limitations of these innovative therapies.